Background: Patients with metabolic syndrome (MetS) are at high coronary risk and beta-cell dysfunction or insulin resistance might predict an additional risk for early cardiovascular events.
Introduction
Recently, closer associations between glucometabolic alterations and coronary artery disease have been established 1, 2 . Glucose abnormalities, observed during the acute phase of coronary syndromes (ACS), increase the risk of adverse outcomes 3, 4 . In addition, those patients with known diabetes mellitus and previous myocardial infarction present the highest risk for cardiovascular mortality 5 .
Several studies have recognized metabolic syndrome (MetS) as an additional risk factor for cardiovascular events, especially among patients with known diabetes mellitus [6] [7] [8] . All these aspects suggest the need of early identification of patients with occult diabetes or presenting glucometabolic abnormalities. In fact, for these patients, a
Fasting plasma lipids (cholesterol, HDL-C, triglycerides) were measured using a standardized kit; LDL-C was estimated by the formula of Friedewald, and apolipoproteins A1 and B were determined by nephelometry. The Oral glucose tolerance test (OGTT, 75 g glucose in 200 ml water) was performed 1-3 days after hospital discharge, after three days of nutrition counseling, based on the NCEP/ATP III guidelines and for appropriate and non-restrictive intake of carbohydrates. The homeostasis model assessment of insulin resistance (HOMA-IR) was calculated as insulin (mU/L) X (glucose [mg/dL] X 0.055)/22.5 12 . For this calculation, we used the mean of three consecutive samples of fasting insulin. The insulinogenic index was calculated as the difference between the 30 min and 0 min OGTT plasma insulin values divided by the difference between the corresponding plasma glucose values (∆I30/∆G30). The area under the curve (AUC) for glucose and insulin were determined based on the blood samples obtained before (t=0) and 30, 60, 90, and 120 min after oral glucose load. Adiponectin was measured by enzyme-linked immunosorbent assay (ELISA) using a commercial kit (Human Adiponectin/ Acrp30 Immunoassay -Quantiquine, R&D Systems). Glycated hemoglobin (HbA1c) was measured using high-performance liquid chromatography.
The severity of coronary atherosclerosis was evaluated through the Gensini score, which depends on the degree of luminal narrowing and importance of the coronary stenosis site 13 . The score evaluates the severity and effects of multiple obstructions, quality of the coronary arteries and the influence of collateral vessels.
To determine differences between the three groups formed after OGTT (NGT, IGT and DM), continuous variables were compared by ANOVA. When necessary, values were logtransformed. Categorical variables were compared using chi-square tests. All tests were 2-tailed, and a p value < 0.05 defined statistical significance. All analyses were performed with SPSS 11.5 for Windows (SPSS Inc, Chicago, IL).
Results
Major characteristics of the study population are shown in Table 1 . One to three days after hospital discharge, only 23% (n=26) of the patients had NGT, while 34% (n=39) had IGT and 43% (n=49) were classified as having DM. In-hospital medical treatment and procedures were similar among the groups. Subjects with NGT, IGT and DM were also comparable regarding age and sex distribution, but higher BMI was observed in DM subjects (p=0.036 vs. NGT), with no differences observed regarding waist circumference. The extension and severity of the coronary artery disease, evaluated by the Gensini score, did not differ among the groups. Lipid and apolipoprotein values were similar among the groups. Fasting plasma glucose values were higher in DM patients, as well as 120 minutes after an oral glucose load (p<0.001 vs NGT and IGT). Fasting insulin values were also higher in DM subjects (p<0.001 vs NGT and p<0.004 vs IGT).
Drug therapies at hospital discharge are shown in Table  2 . The only difference among the groups was the higher prevalence of hypoglycemic drug use in subjects with DM.
HOMA-IR was higher in DM subjects (p<0.001 vs IGT and 
Discussion
In recent years, MetS has been commonly reported among patients with ACS 6, 14 . This study shows, for the first time, the major glucometabolic abnormalities in patients with MetS, but without previously known type 2 diabetes in the acute phase of coronary syndromes.
The OGTT responses performed 1-3 d after hospital discharge disclosed high rates of IGT (34%) and DM (43%). Based on the HOMA-IR, patients with DM were more insulin-resistant than those with NGT or IGT. Furthermore, according to the insulinogenic index (∆I30/∆G30), the betacell responsiveness was also impaired in subjects with DM, when compared with NGT or IGT patients.
Even considering that ACS is a stressful situation, which can explain the high rate of glucometabolic alterations on MetS subjects, these abnormalities are associated with adverse outcomes. Feinberg et al 5 reported, in 1,060 consecutive patients with no previous diagnosis of diabetes, that MetS is an independent predictor of 30-day and 1-year mortality. However, the authors also observed that among those patients, the ones with fasting glycemia > 140 mg/dL were at the highest mortality risk
In our study, we found that insulin resistance was more frequent in patients with no previous diagnosis of DM. The independent association of insulin resistance with coronary disease is still controversial. Tenenbaum et al 15 evaluated the predictive value of HOMA-IR for new major cardiovascular events in 2,938 subjects with preexisting coronary disease. After multivariate analysis, they concluded that insulin resistance is an independent risk factor for cardiovascular events and new-onset diabetes 15 . In the Multi-Ethnic Study of Atherosclerosis (MESA) 2 subclinical atherosclerosis was assessed in 5,810 participants without diabetes and the HOMA-IR was associated with subclinical atherosclerosis; however, the association was not independent after adjustment for nonglucose MetS components.
The present study also showed that DM subjects presented lower beta-cell responsiveness. We used the insulinogenic index to estimate beta-cell function. In comparative studies to evaluate insulin secretion, this index was considered closely related to insulin secretion 16 . In addition, as part of our DM patients were under use of hypoglycemic drugs at hospital discharge, this method appeared to be more sensitive, considering it measures the early insulin response to oral glucose stimulation.
Both insulin deficiency and insulin resistance can be associated with endothelial dysfunction, as insulin-signaling pathways include the production of nitric oxide (NO) and secretion of endothelin-1. In patients with MetS, inflammatory stimuli can cause an additional imbalance between NO production and endothelin-1 secretion, leading to reduced blood flow and impaired glucose uptake in peripheral muscle 17 . In addition, endothelial dysfunction has been related to the development of atherosclerosis and cardiovascular events 18, 19 .
In our study, in-hospital procedures (CABG, percutaneous intervention) and the extension of coronary disease evaluated by the Gensini score were similar among the groups. However, our study was not powered to detect significant differences regarding the burden of atherosclerosis or cardiac events. However, Boulon et al 20 , evaluating the impact of MetS in a follow-up of 480 consecutive patients with ACS, reported an increase in total mortality in the MetS group compared with the non-MetS group 20 . In the Women's Ischemia Syndrome Evaluation (WISE) study, coronary angiography was obtained in 755 women due to suspected myocardial ischemia. When compared with women that presented normal metabolic status, those with MetS had a lower 4-year survival and event-free survival rate (death, nonfatal myocardial infarction, stroke, or congestive heart failure), and when stratified by the presence of significant coronary disease at the angiography, women with MetS were also at higher risk of cardiovascular events 21 .
Recently, studies aimed to evaluate the long-term prognosis of IGT or newly-diagnosed DM after myocardial infarction have identified these glucometabolic abnormalities after OGTT as the strongest predictors of death and major cardiovascular events [22] [23] [24] .
In addition, the Euro Heart Survey showed that 20-30% of patients with either acute coronary syndrome or chronic coronary artery disease presented with newly detected glucose intolerance or diabetes and an OGTT was considered the most appropriate method for the clinical assessment of glucometabolic status in these patients 25 . Finally, the Munich Myocardial Infarction Registry showed the relevance of the in-hospital diagnosis of diabetes mellitus, to promote the early establishment of strategies to reduce cardiovascular mortality 26 , which is endorsed by both the American College of Cardiology/American Heart Association and American Diabetes Association/American College of Endocrinology for glycemic control in patients with acute coronary syndrome, as a Class IIa recommendation 27 .
In conclusion, this study describes high rates of impaired glucose metabolism, including insulin resistance and beta-cell dysfunction, in subjects with MetS at the acute phase of coronary
